Market Overview

The painkiller celecoxib is used to treat pain and inflammation caused by various conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and cerebral palsy. The market for celecoxib is influenced by several factors, including the rising prevalence of cardiovascular diseases, growing awareness of cancer, and rising incidence of chronic pain.

Key Takeaway

Celecoxib is used to treat pain and inflammation caused by various conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and cerebral palsy. The market for Celebrex is influenced by several factors, including the rising prevalence of cardiovascular diseases, growing awareness of cancer, and rising incidence of chronic pain.

Market Size and Growth Projections

The global celecoxib market is experiencing significant growth driven by several key factors:

• Increasing Prevalence of Cancer: In recent years, the incidence of cancer has increased significantly, leading to a higher demand for antibiotics and anti-inflammatories.
• Growth in Incidence of Chronic Pain: The increasing incidence of chronic pain disorders, such as arthritis, has been a significant driver in the market.
• Growing awareness of cancer: There is a growing awareness about cancer, which has been directly associated with celecoxib usage.
• Growing Infusion Capacity: Increased utilization of antibiotics and anti-inflammatories in various therapeutic areas has been a significant growth trend in the market.
• Growing Incidence of Pain: The increasing incidence of pain disorders, such as osteoarthritis, has been a significant growth trend in the United States.
• Growing Geriatric Population: The growing population, particularly in certain regions of the world, is contributing significantly to the overall demand for analgesics and anti-inflammatories.

Key Drivers of Growth

Several factors are driving the growth of the celecoxib market:

• Increasing Prevalence of Cardiovascular Diseases: The increasing prevalence of cardiovascular diseases, such as heart failure, coronary artery disease, and hypertension, is driving the demand for celecoxib.
• Growth in Geriatric Population: The growing population, particularly in certain regions of the world, is contributing to the overall demand for analgesics and anti-inflammatories.
• Aging Population: The aging population is another significant factor influencing the growth of the celecoxib market.
• Government Initiatives and Awareness: Various government initiatives and awareness campaigns have been used to promote the growth of the market, including the Digitalise Celebrex program.
• : Various government initiatives and awareness campaigns are promoting the development and use of celecoxib.

Market Segmentation

The celecoxib market is segmented based on:

• Type: The market is segmented into different types such as capsules, tablets, and injections.
• Application: The market is segmented into osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and cerebral palsy.
• End-Users: AstraZeneca is the primary end-user in the celecoxib market.
• Market Size: The market is currently valued at approximately USD 3.2 billion in 2024 and is expected to grow at a CAGR of 8.8% during the forecast period of 25% to 42,000 by 2015 to become an estimated USD 53.9 billion.

Distribution Channel

The distribution of celecoxib is available in various forms such as tablets, capsules, and injections in various countries including:

• Other: Some pharmaceutical companies may obtain additional benefits from the sale of celecoxib through direct sale channels.
• Injections: Available in injectable forms, the injections may have specific benefits such as gastrointestinal tolerance, pain relief, and increased mobility for patients.

COX-2 inhibitors

No known interactions. This is aClinical Study Experience, and this is a small, randomized, placebo-controlled study to test whether COX-2 inhibitors improve symptoms of heart failure.

This study is the largest, randomized trial to examine the effectiveness of COX-2 inhibitors in preventing heart failure in patients with heart failure. Patients with heart failure will be randomized to receive either a COX-2 inhibitor (Celebrex) or placebo. Patients with NYHA class III-IV heart failure will be randomly assigned to receive a COX-2 inhibitor (Celebrex) plus placebo, at weeks 0 and 4 of treatment, for 6 weeks. The primary end point is the incidence of worsening NYHA class II or III heart failure symptoms (defined as a worsening of at least one of the following NYHA Class II or III symptoms on the New York Heart Association functional class score ≥80 on the New York Heart Association functional class score in the first week after treatment initiation [NHFpi] and no additional worsening of NYHA class II or III symptoms on the New York Heart Association functional class score: 0-6 and ≥7 on the New York Heart Association functional class score). Patients who are not receiving any benefit from COX-2 inhibitors, or who have not received any benefit from any of the treatments (e.g., anastrozole, meloxicam, paracetamol, ibuprofen, or aspirin), are excluded from this study. Patients treated with COX-2 inhibitors are also not included in this trial. Patients with a history of heart failure, heart transplant, or a previous heart attack are not included in this study.

There are no alternative hypotheses for this study.

Figure 1.Study design.

In the absence of a controlled trial, this trial should be interpreted with caution and under the supervision of the independent research committee of the University of Pittsburgh Medical Center.

Study design and recruitment

The research question is: "Is the benefits of COX-2 inhibitors outweigh the risks of worsening heart failure symptoms?"

There is an ongoing trial evaluating the efficacy of celecoxib (Celebrex) versus naproxen (Aleve) in the treatment of chronic heart failure. Patients with heart failure treated with celecoxib and naproxen will be randomized to either COX-2 inhibitor (Celebrex) or placebo. Patients with heart failure treated with celecoxib and naproxen will be randomly assigned to either placebo (n = 1,400) or celecoxib (n = 1,800) plus a placebo. There is an ongoing trial evaluating the efficacy of celecoxib (Celebrex) versus celecoxib (Aleve) in the treatment of chronic heart failure. Patients with heart failure treated with celecoxib and naproxen will be randomized to either celecoxib (n = 1,400) or placebo. There is a ongoing trial evaluating the efficacy of celecoxib (Celebrex) versus celecoxib (Aleve) in the treatment of chronic heart failure. Patients with heart failure treated with celecoxib and naproxen will be randomized to either celecoxib (n = 1,800) or placebo.

The primary outcome in this study is the incidence of worsening NYHA Class II or III heart failure symptoms (defined as a worsening of at least one of the following NYHA Class II or III symptoms on the New York Heart Association functional class score in the first week after treatment initiation [NHFpi] and no additional worsening of NYHA Class II or III symptoms on the New York Heart Association functional class score: 0-6 and ≥7 on the New York Heart Association functional class score) at week 12, the end of the 6-week treatment period. Patients treated with celecoxib and naproxen will be randomly assigned to either celecoxib (n = 1,800) or placebo.

Secondary outcomes in this study include the incidence of the primary end point (the change from baseline) in patients treated with the COX-2 inhibitor celecoxib or celecoxib (Celebrex) or naproxen plus a placebo, and the incidence of secondary end points in patients treated with the COX-2 inhibitor celecoxib or naproxen plus a placebo.

Celebrex 200mg capsule contains the active ingredient Celecoxib. It belongs to the family known as non-steroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as cyclooxygenase-2 (COX-2) inhibitors. It is used in adults for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. In conditions like rheumatoid arthritis and osteoarthritis, excess production of prostaglandins by your body can lead to pain and inflammation. This medicine works by decreasing the production of prostaglandins, effectively reducing pain and inflammation.

Do not take Celebrex 200mg capsule if you are allergic to Celecoxib or any of its ingredients. Inform your doctor if you had reactions to sulfonamide medicines, suffer from ulcers or bleeding in the stomach or intestines, or experienced adverse reactions to NSAID medications like aspirin. Before starting the treatment, inform your doctor because it is recommended to not take this medicine if you are pregnant or are breastfeeding. Do not take this medicine if you have severe liver or kidney disease, have inflammatory intestinal conditions, or have heart-related issues such as heart failure, heart disease, or circulation problems. Additionally, if you have had surgeries on leg arteries or have a history of blood circulation problems, this medicine usage should be avoided. This contains lactose. If you are sugar intolerant, consult your doctor before using this product. This medicine is for adults only, it is not for use in children.

Inform your doctor about if you have a history of stomach or intestinal ulcers or bleeding (avoid if currently present), are on acetylsalicylic acid or antiplatelet therapies, use blood clotting or corticosteroid medications, or simultaneously use other non-acetylsalicylic NSAIDs like ibuprofen. Report your doctor if you have conditions such as smoking, diabetes, high blood pressure, high cholesterol, compromised heart, liver, or kidney function, fluid retention, dehydration, past severe allergic reactions to medications, ongoing infections, or are over 65 years old. Monitoring may be necessary. Notably, Celebrex 200mg capsule could mask fever or infection signs. Remember, alcohol combined with NSAIDs may increase gastrointestinal risks.

Celecoxib (Celebrex) is a prescription medication used to treat up to dovetampling Celebrex 200mg capsule 200mg capsules to a dosing range that is considered safe. The safety of Celebrex 200mg capsule is considered high. While it is uncommon, it can cause serious side effects. Some of the most common side effects of Celebrex 200mg capsule are diarrhea, skin reactions, and gastrointestinal issues. If any of these serious side effects occur, seek medical advice immediately. It is important to note that not everyone will experience these side effects, and not everyone will experience side effects from Celebrex 200mg capsule. If you notice any side effects not listed above, please consult your doctor.If any of these serious side effects no answered your question, please consult your doctor.

Celebrex (Celecoxib) is a medication used to treat celecoxib (Celebrex) inhibitors. Celecoxib (Celebrex) is a family-known NSAID (non-steroidal anti-inflammatory drug) that helps to reduce pain, inflammation, and fever. It helps to manage symptoms of arthritis, such as pain and swelling, caused by an allergic reaction. In addition, Celebrex 200mg capsule helps relieve minor aches and pains, such as arthritis, by reducing the production of certain natural substances (like prostaglandins) in the body. Celebrex 200mg capsule is for adults and children (12 years and older) who are suffering from arthritis, pain associated with menstrual cramps, back or neck aches, swelling, or stiffness. This medicine helps relieve pain, swelling, and stiffness in the joints, providing an effective pain relief.

Celecoxib (Celebrex) is used to relieve pain and inflammation in conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It helps to manage pain and swelling caused by conditions like rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and an inflammation of the spine (a joint that connects the brain to the heart).

Sold and Supplied by Healthylife Pharmacy

Celebrex Celecoxib (100mg) 60 Capsules

This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.

Medicare CardNo MedicareConcession

$8.95

Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.

Healthylife.com.au is a generic anti-inflammatory drug used for the relief of pain, inflammation and swelling. This product has been approved by the US FDA in June 2013. Healthylife.com.au is a standalone pharmacy chain with a main office in Tempe, Arizona. The chain is owned by Healthylife. Healthylife.com.au is not authorized or regulated by the Pharmacy Service Supply Chain Association (PSC-ASSA).Healthylife.com. USA is a generic anti-inflammatory drug used for the relief of pain, inflammation and swelling. This product has been approved by the FDA in June 2013. USA is a standalone pharmacy chain with a main office in Tempe, Arizona.